

Myocardial Injury After COVID-19 Vaccine-Associated Myocarditis: Natural History

Muhammad Mustafa Alhussein

*Corresponding author

Muhammad Mustafa Alhussein, MD
Stephenson Cardiac Imaging Centre, Libin Cardiovascular
Institute, University of Calgary, Calgary, Alberta, Canada

Received Date: July 15, 2022

Accepted Date: July 16, 2022

Published Date: Aug 16, 2022

Abstract

Background : An uncommon side effect of the mRNA-based COVID-19 vaccine is acute myocarditis. The natural history of this problem is poorly understood.

Methods : In 20 consecutive patients meeting the criteria, baseline and convalescent cardiac magnetic resonance (CMR) imaging evaluations were carried out. current Lake Louise mRNA-based vaccination criteria within 10 days of acute myocarditis. Between baseline and convalescence, CMR-based changes in left ventricular volumes, mass, ejection fraction (LVEF), tissue inflammation markers (native T1 and T2 mapping), and fibrosis markers (late gadolinium enhancement [LGE] and extracellular volume [ECV]) were evaluated. Clinical results and cardiac symptoms were recorded.

Conclusions : Beyond three months of recovery in this young patient group, COVID-19 mRNA vaccine-associated myocarditis demonstrated rapid improvements in CMR-based indices of edema, contractile function, and overall LGE burden. However, regional fibrosis after edema resolution was frequently seen, which supported the need for continuous observation.

Methods

Within 10 days of getting an mRNA-based test, 20 adult patients (age 18) were diagnosed with acute myocarditis.

From June 2021 to December 2021, people received the COVID-19 vaccine. Patients had to meet CMR-based diagnostic criteria for acute myocarditis by the Updated Lake Louise Criteria and have a high clinical suspicion of acute

myocarditis based on the Diagnostic Criteria of the European Society of Cardiology²⁰. 14 All participants underwent baseline blood sampling, 12-lead electrocardiography, chest X-rays, and clinical evaluations in addition to CMR imaging. A thorough health questionnaire was filled out, covering demographics, current heart symptoms, inflammatory disease history from the past, and concomitant conditions. After at least three months after recuperation, patients were then required to go through another CMR imaging, fill out questionnaires, and have their medical records reviewed. Informed Under the Cardiovascular Imaging Registry of Calgary, patient permission was sought (CIROC; NCT04367220).

3 Tesla scanners were used for CMR imaging (Prisma or Skyra, Siemens Healthineers). The imaging procedure included native T1 mapping using a modified lock-locker inversion recovery (MOLLI) technique, T2 mapping using a T2-prepared gradient echo technique, black blood T2-weighted imaging using a spectral presaturation attenuated inversion recovery (SPAIR) technique, and black blood T2-weighted imaging prior to contrast infusion of 0.15 mmol/kg gadolinium (Gadovist, Bayer). Ten minutes following the delivery of contrast, short- and long-axis images of late gadolinium enhancement (LGE) imaging were obtained using a phase-sensitive inversion recovery (PSIR) pulse sequence, followed by repeated T1 mapping to determine the extracellular volume (ECV).

CONCLUSION

The COVID-19 mRNA vaccine-associated myocarditis showed rapid improvements in CMR-based indicators of edema, contractile function, and overall LGE load after three months of recovery in this young patient cohort. Regional fibrosis, however, was frequently observed following edema resolution, supporting the necessity for ongoing surveillance.

References

1. Bloomberg. Covid-19 tracker. Available at: <https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/>.
2. Abu Mouch S, Roguin A, Hellou E, et al. Myocarditis following Covid19 mRNA vaccination. Vaccine 2021;39:3790-3.
3. Kim RJ, Kim HW, Jenista ER, et al. Patients with acute

- myocarditis following mRNA covid-19 vaccination. *JAMA Cardiol* 2021;6:1196-201.
4. Ryan M, Montgomery J, Engler R, et al. Myocarditis following immunization with mRNA Covid-19 vaccines in members of the us military. *JAMA Cardiol* 2021;6:1202-6.
 5. Patel YR, Louis DW, Atalay M, Agarwal S, Shah NR. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA Covid-19 vaccination: a case series. *J Cardiovasc Magn Reson* 2021;23:1-8.
 6. Shaw KE, Cavalcante JL, Han BK, Gössl M. Possible association between Covid-19 vaccine and myocarditis: clinical and CMR findings. *JACC Cardiovasc Imaging* 2021;14:1856-61.
 7. Rosner CM, Genovese L, Tehrani BN, et al. Myocarditis temporally associated with Covid-19 vaccination. *Circulation* 2021;10:1-9.
 8. David Hana KP, Sherif Roman BG, Sofka S. Clinical cardiovascular adverse events reported postCovid-19 vaccination: are they a real risk? *Curr Probl Cardiol* 2022;47:101077.
 9. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson RAIV. Myocarditis and pericarditis after vaccination for Covid-19. *JAMA* 2021;326:1210-2.
 10. Simone A, Herald J, Chen A, et al. Acute myocarditis following Covid-19 mRNA vaccination in adults aged 18 years or older. *JAMA Intern Med* 2021;181:1668-70.
 11. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based Covid-19 vaccination in the US from December 2020 to August 2021. *JAMA* 2022;327:331-40.
 12. Fazlollahi A, Zahmatyar M, Noori M, et al. Cardiac complications following mRNA Covid-19 vaccines: a systematic review of case reports and case series. *Rev Med Virol* 2022;32:e2318.
 13. Tijmes FS, Thavendiranathan P, Udell JA, Seidman M, Hanneman K. Cardiac mri assessment of nonischemic myocardial inflammation: State of the art review and update on myocarditis associated with covid-19 vaccination. *Radiol Cardiothorac Imaging* 2021;3:e210252.
 14. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. *J Am Coll Cardiol* 2018;72:3158-76.
 15. Luetkens JA, Homsy R, Dabir D, et al. Comprehensive cardiac magnetic resonance for short-term follow-up in acute myocarditis. *J Am Heartm Assoc* 2016;5:e003603.
 16. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis diagnosis, treatment options, and current controversies. *Nat Rev Cardiol* 2015;12:670-80.
 17. Bohnen S, Radunski UK, Lund GK, et al. Tissue characterisation by T1 and T2 mapping cardiovascular magnetic resonance imaging to monitor myocardial inflammation in healing myocarditis. *Eur Heart J Cardiovasc Imaging* 2017;18:744-51.
 18. Von Knobelsdorff-Brenkenhoff F, Schüler J, Dogangüzel S, et al. Detection and monitoring of acute myocarditis applying quantitative cardiovascular magnetic resonance. *Circ Cardiovasc Imaging* 2017;10: 1-10.
 19. Bozkurt B, Kamat I, Hotez PJ. Myocarditis with Covid-19 mRNA vaccines. *Circulation* 2021 2019:471-84.
 20. Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on etiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013;34:2636-48.
 21. Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardised image interpretation and post-processing in cardiovascular magnetic resonance 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR); Board of Trustees Task Force on Standardised Post-Processing. *J Cardiovasc Magn Reson* 2020;22:19
 22. Kawel-Boehm N, Maceira A, Valsangiacomo-Buechel

- ER, et al. Normal values for cardiovascular magnetic resonance in adults and children. *J Cardiovasc Magn Reson* 2015;17:29.
23. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organisation. *N Engl J Med* 2021;385:2132-9.
 24. Gellad WF. Myocarditis after vaccination against Covid-19. *BMJ* 2021;375:n3090.
 25. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. *N Engl J Med* 2021;385:2140-9.
 26. Dionne A, Sperotto F, Chamberlain S, et al. Association of myocarditis with BNT162b2 messenger RNA Covid-19 vaccine in a case series of children. *JAMA Cardiol* 2021;6:1446-50.
 27. Fronza M, Thavendiranathan P, Chan V, et al. Myocardial injury pattern at MRI in COVID-19 vaccine-associated myocarditis. *Radiology*
 28. Sanguineti F, Garot P, Mana M, et al. Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis. *J Cardiovasc Magn Reson* 2015;17:78.
 29. Gräni C, Eichhorn C, Bière L, et al. Prognostic Value of cardiac magnetic resonance tissue characterisation in risk stratifying patients with suspected myocarditis. *J Am Coll Cardiol* 2017;70:1964-76.
 30. Aquaro GD, Perfetti M, Camastra G, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. *J Am Coll Cardiol* 2017;70:1977-87.
 31. Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. *Circulation* 2016;134:e579-646.
 32. Cavalcante J, Shaw K, Gössl M, et al. Cardiac magnetic resonance imaging midterm follow up of Covid-19 vaccine-associated myocarditis. *JACC Cardiovasc Imaging* 2022;15:1821-182.
 33. White JA, Hansen R, Abdelhaleem A, et al. Natural history of myocardial injury and chamber remodelling in acute myocarditis: a 12-month prospective cohort study using cardiovascular magnetic resonance imaging. *Circ Cardiovasc Imaging* 2019;12:e008614.
 34. Grun S, Schumm J, Greulich S, et al. Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. *J Am Coll Cardiol* 2012;59:1604-15.
 35. Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. *Circ Heart Fail* 2020;13:e007405.
 36. Luk A, Clarke B, Dahdah N, et al. Myocarditis and pericarditis after Covid-19 mRNA vaccination: practical considerations for care providers. *Can J Cardiol* 2021;37:1629-34. 2022;304:553-62